Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

Korábbi kezelés

• Concurrent biologics for asthma are not allowed. Acceptable wash-out periods for other asthma biologics: ≥30 days from the last dose of the previous biologic.

Más betegség

• Clinically important pulmonary diseases other than asthma including chronic obstructive pulmonary disease (as the main diagnosis), bronchiectasis, idiopathic pulmonary fibrosis, pulmonary hypertension, alpha-1-antitrypsin-deficiency, and malignancy of any kind (NB: the following conditions are permitted: nasal polyposis, allergic rhinitis, atopic dermatitis, non-idiopathic pulmonary fibrosis).
• An acute or chronic condition that, in the investigator's opinion, would limit the patients' ability to complete questionnaires or participate in this study or impact the interpretations of results.

Egyéb

• Currently enrolled in an interventional clinical study except patients being in parallel documented in a national asthma registry
• Women who are currently pregnant, breastfeeding, or lactating

• Male or female patients aged 18 years or older with a physician's confirmed diagnosis of severe eosinophilic, uncontrolled asthma.
• Severe uncontrolled eosinophilic asthma requiring high-dose* inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment.
• Patients who have been prescribed but not yet initiated treatment with benralizumab (Fasenra®) according to local approved prescribing information prior to signed informed consent.
• Provision of the signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.
• Patients must be able and willing to read and comprehend written instructions and complete the paper PRO questionnaires required by the protocol.